Additionally, butyrate (HDAC inhibitor) inhibits SLC7A11 transcription by upregulating ATF3 expression and promoting ferroptosis in osteosarcoma cells, thus alleviating osteosarcoma (Nie et al. 2023). Here, ATF3 is linked to osteosarcoma.